他汀类药物治疗冠心病效果的粪便代谢组学特征

doi:10.16352/j.issn.1001-6325.2026.01.0063

基础医学与临床 ›› 2026, Vol. 46 ›› Issue (1): 63-70.doi: 10.16352/j.issn.1001-6325.2026.01.0063

他汀类药物治疗冠心病效果的粪便代谢组学特征

李若宁, 许良, 赵迎春, 邵冀青, 居博伟^*

新疆医科大学第五附属医院药学部,新疆乌鲁木齐 830000

收稿日期:2025-01-14 修回日期:2025-04-29 出版日期:2026-01-05 发布日期:2025-12-29
通讯作者: ^*17726860519@163.com
基金资助:
新疆维吾尔自治区自然科学基金(2022D01C579);新疆医科大学大学生创新创业训练计划(S202310760062);新疆医科大学第五临床医学院(第五附属医院)国家自然科学基金启航项目(XYDWFY-GQH-2024-19);新疆维吾尔自治区2023年第二批天山英才培养计划青年托举人才项目(2023TSYCQNTJ0025)

Characteristics of fecal metabolomics about therapeutic effects of statins for coronary heart disease

LI Ruoning, XU Liang, ZHAO Yingchun, SHAO Jiqing, JU Bowei^*

Department of Pharmacy, the Fifth Affiliated Hospital of Xinjiang Medical University,Urumqi 830000,China

Received:2025-01-14 Revised:2025-04-29 Online:2026-01-05 Published:2025-12-29
Contact: ^*17726860519@163.com

摘要/Abstract

摘要： 目的探索粪便代谢组学特征与他汀类药物治疗效果之间的关系。方法收集60例接受他汀类药物治疗的冠心病患者的粪便样本,根据治疗后低密度脂蛋白(LDL)水平是否低于1.9 mmol/L,将患者分为治疗有效组(30例)和治疗无效组(30例)。对粪便样本进行非靶向代谢组学和靶向短链脂肪酸测序,并对测序结果进行数据分析。结果主成分分析(PCA)显示治疗有效组与治疗无效组之间存在显著差异。差异分析发现,在正离子模式和负离子模式下共有319个离子在两组间显著不同。富集分析表明,牛磺酸和次牛磺酸代谢、核黄素代谢、脂肪酸代谢等多个通路被富集。基于113个诊断模型,筛选出对治疗有效性预测能力最强的前10个模型,其中Prilocaine、Glufosinate和His-Gly-His在所有模型中均表现出较高的预测能力曲线下面积[(AUC)均大于0.6]。Prilocaine和His-Gly-His在治疗有效组中的水平显著高于治疗无效组,而Glufosinate在治疗有效组中的水平则较低(P＜0.05)。此外,短链脂肪酸测序结果显示丙酸和丁酸在治疗有效组中的水平显著低于治疗无效组(P＜0.01)。相关性分析显示丙酸和丁酸与Prilocaine呈负相关,与His-Gly-His呈正相关。结论他汀类药物治疗效果与粪便代谢组学特征之间的关联,尤其是Prilocaine、Glufosinate和His-Gly-His等代谢物的水平变化可能受到短链脂肪酸的调控,并对治疗效果具有预测价值。

关键词: 冠心病, 他汀类药物, 肠道代谢物, 短链脂肪酸

Abstract: Objective To explore the relationship between fecal metabolomics characteristics and the therapeutic effects of statins. Methods Fecal samples were collected from 60 patients with coronary heart disease undergoing statin therapy. Based on whether their low-density lipoprotein (LDL) level were below 1.9 mmol/L after treatment, the patients were divided into an effective treatment group and ineffective treatment group with 30 cases in each. Non-targeted metabolomics and targeted short-chain fatty acid sequencing were performed with the fecal samples and the sequencing results were analyzed. Results Principal Component Analysis (PCA) showed significant differences between the effective and ineffective treatment groups. Differential analysis identified 319 ions significantly different between the two groups in positive ion mode and negative ion mode. Enrichment analysis indicated that several pathways including taurine and hypotaurine metabolism, riboflavin metabolism, and fatty acid metabolism were enriched. Based on 113 diagnostic models, the top 10 models with the best predictive ability for treatment efficacy were selected, with Prilocaine, Glufosinate, and His-Gly-His showing the highest predictive capability across all models [area under the curve(AUC＞0.6)]. The level of Prilocaine and His-Gly-His was higher in effective treatment group while the level of Glufosinate was lower in the effective treatment group (P＜0.05). Additionally, short-chain fatty acid sequencing results showed that the level of Butyric acid and Propionic acid were significantly lower in the effective treatment group (P＜0.01). Butyric acid and Propionic acid were negatively correlated with Prilocaine and positively correlated with His-Gly-His. Conclusions The association between the efficacy of statins therapy and fecal metabolomics characteristics highlights the predictive value of changes in metabolite level such as Prilocaine, Glufosinate, and His-Gly-His which are potentially regulated by short-chain fatty acids.

Key words: coronary heart disease, statins, intestinal metabolites, short chain fatty acids

中图分类号:

R135.2

李若宁, 许良, 赵迎春, 邵冀青, 居博伟. 他汀类药物治疗冠心病效果的粪便代谢组学特征[J]. 基础医学与临床, 2026, 46(1): 63-70.

LI Ruoning, XU Liang, ZHAO Yingchun, SHAO Jiqing, JU Bowei. Characteristics of fecal metabolomics about therapeutic effects of statins for coronary heart disease[J]. Basic & Clinical Medicine, 2026, 46(1): 63-70.

参考文献

[1]Chen W, Ni M, Huang H, et al. Chinese expert consensus on the diagnosis and treatment of coronary microvascular diseases (2023 Edition)[J]. Med Comm (2020), 2023, 4:e438. doi: 10.1002/mco2.438.
[2]Chung J, Kim HL, Lim WH, et al. New onset diabetes mellitus and cardiovascular outcomes according to statin intensity in patients after drug-eluting stent implantation in Asian patients[J]. Sci Rep, 2023, 13: 16061. doi: 10.1038/s41598-023-42277-w.
[3]Nguyen XT, Ho YL, Li Y, et al. Serum cholesterol and impact of age on coronary heart disease death in more than 4 million veterans[J]. J Am Heart Assoc, 2023, 12:e030496. doi: 10.1161/JAHA.123.030496.
[4]Deng CJ, Yan J, Zheng YY, et al. Effectiveness of lipid-lowering therapy on mortality and major adverse cardiovascular event outcomes in patients undergoing percutaneous coronary intervention: a network meta-analysis of randomised controlled trials[J]. BMJ Open, 2023, 13:e070827. doi: 10.1136/bmjopen-2022-070827.
[5]Fan Y, Wang J, Wu H, et al. Effect of statin treatment on mortality in elderly patients with type 2 diabetes mellitus patients: a retrospective cohort study[J]. BMC Geriatr, 2023, 23:549. doi: 10.1186/s12877-023-04252-y.
[6]Hu L, Hu B, Zhang L, et al. Role of gut microbiota and metabolomics in the lipid-lowering efficacy of statins among Chinese patients with coronary heart disease and hypercholesterolemia[J]. Front Cell Infect Microbiol, 2024, 14: 1408581. doi: 10.3389/fcimb.2024.1408581.
[7]冠状动脉粥样硬化性心脏病诊断标准[S]. 卫生部医疗服务标准专业委员会, 2010.
[8]Liu Z, Liu L, Weng S, et al. Machine learning-based integration develops an immune-derived lncRNA signature for improving outcomes in colorectal cancer[J]. Nat Commun, 2022, 13:816. doi: 10.1038/s41467-022-28421-6.
[9]Dabiri H, Mortezaei Z. Genome-wide association study of therapeutic response to statin drugs in cardiovascular disease[J]. Sci Rep, 2024, 14:18005. doi: 10.1038/s41598-024-68665-4.
[10]Lv L, Yan L, Liu X, et al. Effectiveness of lidocaine/prilocaine cream on cardiovascular reactions from endotracheal intubation and cough events during recovery period of older patients under general anesthesia: prospective, randomized placebo-controlled study[J]. BMC Geriatr, 2020, 20:157. doi: 10.1186/s12877-020-01567-y.
[11]Wilmanski T, Kornilov SA, Diener C, et al. Hetero-geneity in statin responses explained by variation in the human gut microbiome[J]. Med, 2022, 3:388-405. doi: 10.1016/j.medj.2022.04.007.
[12]Wang J, Zhang X, Yang X, et al. Revitalizing myocarditis treatment through gut microbiota modulation: unveiling a promising therapeutic avenue[J]. Front Cell Infect Microbiol, 2023, 13: 1191936. doi: 10.3389/fcimb.2023.1191936.
[13]Wang X, Li D, Xu Y, et al. Xylanase supplement enhances the growth performance of broiler by modulating serum metabolism, intestinal health, short-chain fatty acid composition, and microbiota[J]. Animals (Basel), 2024, 14:1182. doi: 10.3390/ani14081182.
[14]Masse KE, Lu VB. Short-chain fatty acids, secondary bile acids and indoles: gut microbial metabolites with effects on enteroendocrine cell function and their potential as therapies for metabolic disease[J]. Front Endocrinol (Lausanne), 2023, 14: 1169624. doi: 10.3389/fendo.2023.1169624.
[15]Luqman A, Hassan A, Ullah M, et al. Role of the intestinal microbiome and its therapeutic intervention in cardiovascular disorder[J]. Front Immunol, 2024, 15: 1321395. doi: 10.3389/fimmu.2024.1321395.

他汀类药物治疗冠心病效果的粪便代谢组学特征

Characteristics of fecal metabolomics about therapeutic effects of statins for coronary heart disease

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 12

编辑推荐

Metrics

本文评价

[1]	陈延勋, 赵飞龙, 杨靖. 血清miR-185-3p和miR-3194-5p水平与冠状动脉病变严重程度的相关性[J]. 基础医学与临床, 2025, 45(8): 1041-1047.
[2]	陈文杰, 刘怡铭, 史雨晨, 柳景华. 人工智能在冠心病临床诊疗中的应用与挑战:从影像学分析到多组学联合[J]. 基础医学与临床, 2025, 45(2): 160-167.
[3]	韩丽杰, 胡朝伟, 于华惠, 秦彦文. 血管生成素样蛋白8在心血管疾病发病中作用的研究进展[J]. 基础医学与临床, 2024, 44(4): 544-547.
[4]	宋星明, 哈力沙·艾日肯江, 迪丽胡玛尔·阿布来提, 高颖. 内皮脂肪酶作为冠心病治疗靶点的研究进展[J]. 基础医学与临床, 2023, 43(9): 1443-1447.
[5]	石阳, 毕晓磊, 邵一兵. 冬泳在急性心肌梗死发病学中作用的研究进展[J]. 基础医学与临床, 2022, 42(12): 1921-1924.
[6]	高川, 周俞余, 高莹, 何仲. 稳定性冠心病诊疗中患者参与临床决策质量及其影响因素[J]. 基础医学与临床, 2022, 42(10): 1572-1576.
[7]	叶阿里, 邹雨桐, 张海燕, 吴洁, 张睿, 张晓峰, 马庆伟. MALDI-TOF-MS和RT-qPCR对于SLCO1B1和ApoE多态性检测的比较[J]. 基础医学与临床, 2020, 40(7): 980-985.
[8]	杨玲, 杜雪平. 北京市西城区急性冠脉综合征住院患者的诊断治疗分析[J]. 基础医学与临床, 2020, 40(12): 1681-1685.
[9]	李丽君王晶穆洋徐勇. 血清高密度脂蛋白不同组分与冠状动脉病变的相关性研究[J]. 基础医学与临床, 2018, 38(11): 1558-1562.
[10]	查额尔敦巴特付真彦董春岚王蓓黄定. GP78基因多态性与冠心病相关[J]. 基础医学与临床, 2015, 35(4): 450-453.
[11]	彭洁郭媛. ATP结合盒转运体A1基因变异与冠心病的研究进展[J]. 基础医学与临床, 2012, 32(9): 1107-1110.
[12]	李文龙王晓建徐菁陈敬洲张禅那孙凯惠汝太. CX3CR1基因多态性与冠心病关联的Meta分析[J]. 基础医学与临床, 2009, 29(11): 1170-1173.